UT Health San Antonio (Long School of Medicine)
Hematology and Oncology fellowship · San Antonio, TX · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is The University of Texas at San Antonio Health Science Center's research in hematology and oncology, which the program shares with other departments and affiliated hospitals.
About The University of Texas at San Antonio Health Science Centerinstitution-wide hematology and oncology research
Hematology and Oncology publications from The University of Texas at San Antonio Health Science Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
105
works per year
40th of 74 hematology and oncology fellowship programs
-8.6%
2-year growth
67th of 74 hematology and oncology fellowship programs
27.0%
in top 10% of field (works before 2025)
25th of 72 hematology and oncology fellowship programs
43.6%
cited above world average
33rd of 72 hematology and oncology fellowship programs
Works per year · * 2026 so far
Oncology · 374Hematology · 129
Hematology and Oncology research topics at The University of Texas at San Antonio Health Science Center
Papers in the window; each links to the list on OpenAlex.
- Cancer Immunotherapy and Biomarkers 66
- Cancer survivorship and care 42
- Acute Myeloid Leukemia Research 39
- Pancreatic and Hepatic Oncology Research 33
- Cutaneous Melanoma Detection and Management 25
- Hematopoietic Stem Cell Transplantation 21
- COVID-19 and healthcare impacts 19
- Global Cancer Incidence and Screening 18
Most cited at The University of Texas at San Antonio Health Science Center since 2024
All hematology and oncology papers there on OpenAlex
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber et al. · The Lancet · 2024 · PubMed · cited 958
- Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trialAndrea J. Bullock et al. · Nature Medicine · 2024 · PubMed · cited 159
- SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockadeAdam Grippin et al. · Nature · 2025 · PubMed · cited 151
- Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1 -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical SubgroupsAditya Bardia et al. · Clinical Cancer Research · 2024 · PubMed · cited 124
- RNA m5C oxidation by TET2 regulates chromatin state and leukaemogenesisZhongyu Zou et al. · Nature · 2024 · PubMed · cited 95
- Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialAlexander Gerhard Miethke et al. · The Lancet. Gastroenterology & hepatology · 2024 · PubMed · cited 78
- The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunitiesHeng‐Chung Kung et al. · Nature Reviews Clinical Oncology · 2025 · PubMed · cited 72
- Screening and Supplementation for Iron Deficiency and Iron Deficiency Anemia During PregnancyUS Preventive Services Task Force et al. · JAMA · 2024 · PubMed · cited 62
- Clinical development of immuno-oncology therapeuticsJianxin Wang et al. · Cancer Letters · 2025 · PubMed · cited 57
- The Role of the Tumor Microenvironment (TME) in Advancing Cancer Therapies: Immune System Interactions, Tumor-Infiltrating Lymphocytes (TILs), and the Role of Exosomes and InflammasomesAtef M. Erasha et al. · International Journal of Molecular Sciences · 2025 · PubMed · cited 49